Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Activation in transformed cells of normal stem cells' self-renewal pathways might contribute to the survival life cycle of cancer stem cells and promote tumor progression. The BMI-1 oncogene-driven gene expression pathway is essential for the self-renewal of hematopoietic and neural stem cells. We applied a mouse/human comparative translational genomics approach to identify an 11-gene signature that consistently displays a stem cell-resembling expression profile in distant metastatic lesions as revealed by the analysis of metastases and primary tumors from a transgenic mouse model of prostate cancer and cancer patients. To further validate these results, we examined the prognostic power of the 11-gene signature in several independent therapy-outcome sets of clinical samples obtained from 1,153 cancer patients diagnosed with 11 different types of cancer, including 5 epithelial malignancies (prostate, breast, lung, ovarian, and bladder cancers) and 5 nonepithelial malignancies (lymphoma, mesothelioma, medulloblastoma, glioma, and acute myeloid leukemia). Kaplan-Meier analysis demonstrated that a stem cell-like expression profile of the 11-gene signature in primary tumors is a consistent powerful predictor of a short interval to disease recurrence, distant metastasis, and death after therapy in cancer patients diagnosed with 11 distinct types of cancer. These data suggest the presence of a conserved BMI-1-driven pathway, which is similarly engaged in both normal stem cells and a highly malignant subset of human cancers diagnosed in a wide range of organs and uniformly exhibiting a marked propensity toward metastatic dissemination as well as a high probability of unfavorable therapy outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated expression of this signature is associated with cancer development and chemotherapy resistance in different types of cancer, including hematological malignancies.11”
From USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism (2018) · cites this paper as [11]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536 · cited 4×
“We therefore sought to investigate whether measurements of expression of the 11-gene MTTS/PNS signature would be informative in the prediction of the patients’ prognosis in a group of 97 young women diagnosed with sporadic lymph node– negative early-stage breast cancer who were analyzed in a recent expression profilin…”
BackgroundMethodInfluentialA Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717
Bhattacharjee, A., Richards, W. G., Staunton, J., Li, C., Monti, S., Vasa, P., Ladd, C., Beheshti, J., Bueno, R., Gillette, M., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191502998 · Cited by 2,576
Gene expression correlates of clinical prostate cancer behavior
Singh, D., Febbo, P. G., Ross, K., Jackson, D. G., Manola, J., Ladd, C., Tamayo, P., Renshaw, A. A., D'Amico, A. V., Richie, J. P., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00030-2 · Cited by 2,512
Systematic determination of genetic network architecture
Tavazoie, S., Hughes, J. D., Campbell, M. J., Cho, R. J., & Church, G. M. (1999) · Nature Genetics · doi:10.1038/10343 · Cited by 2,507 · cited 1×
“We calculated the significance of the overlap between the lists of stem cell–associated and prostate cancer–associated genes by using the hypergeometric distribution test (54).”
MethodA molecular signature of metastasis in primary solid tumors
Ramaswamy, S., Ross, K. N., Lander, E. S., & Golub, T. R. (2003) · Nature Genetics · doi:10.1038/ng1060 · Cited by 2,449
Shipp, M. A., Ross, K. N., Tamayo, P., Weng, A. P., Kutok, J. L., Aguiar, R. C. T., Gaasenbeek, M., Angelo, M., Reich, M., Pinkus, G. S., et al. (2002) · Nature Medicine · doi:10.1038/nm0102-68 · Cited by 2,428
Cited by
Items 801–900 of 914
Lin, H., Faith, B., Mary, K., Mousa, S. A., Dhruba, J., & Paul, J. (2012) · InTech eBooks · doi:10.5772/22667 · Cited by 1
“…anti-apoptotic actions of T4 and T3; 2) to disable, in the absence or presence of T4 and T3, the expression of a number of survival pathway genes (Glinsky et al., 2004); and 3) to suppress the death-from-cancer gene signature of a number of cancer cell lines (Glinsky et al., 2005).”
BackgroundNetwork-Guided Key Gene Discovery for a Given Cellular Process
HeFeng, F. Q., & Ollert, M. W. (2016) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2016_39 · Cited by 1
Khalifa, S., Khairy, R. A., & Salah, M. (2016) · Kasr Al Ainy Medical Journal · doi:10.4103/1687-4625.195890 · Cited by 1
Bmi-1 serves as a potential novel marker for progression in human cutaneous basal cell carcinoma.
Zhu, H., Wu, J., Cui, X., & Chen, X. (2017) · PubMed Central · Cited by 1
Mesothelioma Heterogeneity: Potential Mechanisms
Felley-Bosco, E. (2019) · MDPI eBooks · doi:10.3390/books978-3-03897-474-1 · Cited by 1
The Role of Epigenetic Modifications in Cancer
Powell, M. J., Popov, V. M., Wang, X., McMahon, S. B., Mazo, A., & Pestell, R. G. (2011) · Wiley eBooks · doi:10.1002/9781118005743.ch7 · Cited by 1
Development of novel combinatorial treatment strategies to overcome resistance in breast cancer
Oak, P. (2012) · Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.14196 · Cited by 1
Genetic Markers in Prostate Cancer: Progress and Limitations
Čulig, Z. (2012) · European Urology · doi:10.1016/j.eururo.2012.06.040 · Cited by 1
“The authors state correctly that many reports in the literature contain data on possible genetic markers that distinguish between less andmore aggressive tumors [9,10].”
BackgroundMatsumoto, R. (2016) · International Journal of Urology · doi:10.1111/iju.13245 · Cited by 1
Distinct roles of FGFR1 and FGFR2 in regulating cell survival and epithelial-mesenchymal transition
Xian, W., Schwertfeger, K. L., & Rosen, J. M. (2007) · Cited by 1
Investigations into the regulation of histone H2B monoubiquitination
Shchebet, A. (2011) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-507 · Cited by 1
Epigenetic regulation of osteoblast differentiation
Najafova, Z. (2017) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-6333 · Cited by 1
Role of ASXL1 in Tumorigenesis and EMT in Breast Cancer
Budida, A. (2017) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-6158 · Cited by 1
The role and regulation of histone H2B monoubiquitination during tumorigenesis
Gorsler, T. (2014) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-4504 · Cited by 1
Distilling the Past – Envisioning the Future
Ablin, R. J., & Mason, M. D. (2007) · Springer eBooks · doi:10.1007/978-1-4020-5847-9_16 · Cited by 1
Sun, S. B., Schiller, J. H., Spinola, M., & Minna, J. D. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-524-8_20
“The identification of cancer stem cell markers may also be useful for early detection and provide predictive and prognostic information ( 39 , 40).”
BackgroundNalwoga, H. (2010) · NVA (Nasjonalt vitenarkiv) · Cited by 4
Mannelqvist, M. (2011) · NVA (Nasjonalt vitenarkiv)
Bullinger, L., Döhner, H., & Pollack, J. R. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-576-3_8
Dissecting the Molecular Mechanism of RhoC GTPase Expression in the Normal and Malignant Breast
Brenner, J. C. (2011) · Defense Technical Information Center (DTIC) · doi:10.21236/ada562247
Nucleic Acid‐Based Diagnostics in Gynecological Malignancies
Häusler, S. F., Dietl, J., & Wischhusen, J. (2014) · Wiley eBooks · doi:10.1002/9783527672165.ch07
Epigenetics in Cancer Stem Cell Development
Nephew, K. P., Balch, C., Huang, T. H. ‐., Zhang, S., Chan, M. W. Y., & Yan, P. S. (2008) · Wiley eBooks · doi:10.1002/9780470391594.ch10 · Cited by 1
Molecular Profiling for Early Detection and Prediction of Response in Lung Cancer
Kaufman, J. M., & Carbone, D. P. (2008) · Wiley eBooks · doi:10.1002/9780470696330.ch10
Bonnie, W. (2012) · InTech eBooks · doi:10.5772/31727
Integrative statistical methods for the analysis of transcriptomic and metabolomic data
Poisson, L. (2010) · Deep Blue (University of Michigan)
Expression analysis of stress-induced apoptosis pathway regulating genes in B-cell lymphomas
van Galen, J. C. (2008) · Pure Amsterdam UMC
Allen, T. C. (2012) · Molecular pathology library · doi:10.1007/978-1-4614-3197-8_4
BMI Transcription Factor as a Novel Target for the Treatment of Brain Tumors
Hossain, M. M., Meléndez, B., REY, J. A., Castresana, J. S., & Shahi, M. H. (2015) · InTech eBooks · doi:10.5772/59194
Implications of Cancer Stem Cells for Tumor Metastasis
Kalani, M. A., Dalerba, P. D., & Clarke, M. F. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-087-8_38 · Cited by 1
[High-risk clinically localised prostate cancer].
Rozet, F., Cornu, J.-N., Cussenot, O., Fromont, G., & Hennequin, C. (2010) · PubMed · doi:10.1684/bdc.2010.1228 · Cited by 1
Genomic and Epigenomic Studies of Acute Myeloid Leukemia with CEBPA Abnormalities
Wouters, B. J. (2009) · EUR Research Repository (Erasmus University Rotterdam)
Prostate Cancer Stem Cells and Their Involvement in Metastasis
Li, H., & Tang, D. G. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-087-8_39
Studies of murine prostate cancer stem / progenitor cells
Liao, C. (2008) · University of Southern California Digital Library · doi:10.25549/usctheses-m1326
To Divide or Not to Divide; MicroRNAs and Small Compounds as Modulators of Mitosis
Mäki-Jouppila, J. H. (2015) · UTUPub (University of Turku)
Characterization of neuroblastoma stem cells
Ma, J. (2006) · OhioLink ETD Center (Ohio Library and Information Network)
Metzger, O., Bedard, P. L., Ignatiadis, M., & Sotiriou, C. P. (2010) · Hot Topics in Oncology · doi:10.4147/hto-100723
3rdPacRim Breast and Prostate Cancer Meeting
Fuller, P. J. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.3.397
“Ralph Buttyan (University of Chicago, USA) explored the issue of ‘stemness’ in cancer cells, including a recent report in 2005 [12] that an 11-gene signature – which predicted a poor prognosis in a number of tumours including breast and prostate – is seen in stem cells.”
BackgroundReview of: Gene expression profiling identifies molecular subtypes of inflammatory breast cancer
Lønning, P. E. (2006) · Breast Cancer Online · doi:10.1017/s1470903106004731
“[24] reporting a stem-cell signature across tumour forms, may add information to our understanding of the biological mechanisms controlling vital processes in cancer development and behaviour.”
BackgroundEnforced Expression of BMI-1 in Postnatal Human CD34+ Cells Promotes Erythroid Differentiation
Lee, G., Kim, B., Shieh, J.-H., & Moore, M. A. (2007) · The Korean Journal of Hematology · doi:10.5045/kjh.2007.42.3.241
Genome-wide mapping of DNA-protein interactions in eukaryotes
Kim, J. (2005) · Texas ScholarWorks (Texas Digital Library) · Cited by 1
Bioanalytical Microfluidic Devices and Methods for Analysis of Cancer Gene Expression
Bueno, N. D. (2011) · eScholarship (California Digital Library)
Gilarranz, Y. J. (2012) · Journal of Clinical & Experimental Pathology · doi:10.4172/2161-0681.s1-003
“Other genomic profile platforms to evaluate risk in breast cancer have been based on the p53 pathway [63], the oncogenic pathway of the activated ring-finger polycomb protein BMI1 [64], or the Invasiveness Genes Signature (IGS) [65].”
BackgroundGuinney, J. (2009) · DukeSpace (Duke University)
Viewpoint Live or let die: oestrogen regulation of survival signalling in endocrine response
Butt, A. J., Sutherl, R. L., & Musgrove, E. A. (2007)
Zhu, M., Michalowski, A. M., & Green, J. E. (2011) · Springer eBooks · doi:10.1007/978-0-387-69805-2_10
Glinsky, G. V. (2016) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/040519
“The training set of 141 samples was utilized to identify and select the best classifier, whose performance was evaluated on the test set of 140 samples without any further adjustments to the threshold selection and classification protocols using Kaplan-Meyer survival analysis essentially as previously described (16-19…”
BackgroundMethodInfluentialSelf-citationGlinsky, G. V. (2016) · arXiv (Cornell University) · doi:10.48550/arxiv.1602.06504
“The training set of 141 samples was utilized to identify and select the best classifier, whose performance was evaluated on the test set of 140 samples without any further adjustments to the threshold selection and classification protocols using Kaplan-Meyer survival analysis essentially as previously described (16-19…”
BackgroundMethodInfluentialSelf-citationPrimary Glioma Spheroids: Advantage of Serum-Free Medium
Aaberg-Jessen, C., Christensen, K. G., & Kristensen, B. W. (2011) · Springer eBooks · doi:10.1007/978-94-007-1709-1_10
Rosado, J. O., Bonatto, D., & Henriques, J. A. P. (2010) · Americanae (AECID Library) · doi:10.13140/rg.2.2.23777.12647
Chagas disease: Transcriptomic recovery in animal models after transplantation of bone marrow cells
Morel, C. M. (2011) · Cell Cycle · doi:10.4161/cc.10.12.15688
New, clinically relevant molecular characterizations of thyroid cancer
Davis, P. J. (2009) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3283307bd2
PROGNOSTIC FACTORS IN MALIGNANT PLEURAL MESOTHELIOMA
Ambrogi, T. C. M. A. V. (2016)
Polycomb Group Proteins in Tumorigenesis
Voncken, J. W., & Niessen, H. E. C. (2008) · CRC Press eBooks · doi:10.1201/9781420045802.ch16
Shema, E., Tirosh, I., & Aylon, Y. (2008)
Causes and consequences of genomic instability in prostatic carcinogenesis.
Joshua, A. M. (2009) · TSpace (University of Toronto)
Targeting Stem Cell Protein BMI1; A Potential Therapeutic Approach for Prostate Cancer Therapy
Beigh, F. H., Syeed, N., Maqbool, M., & Majumdhar, R. S. (2017) · Journal of Stem Cell Research & Therapy · doi:10.4172/2157-7633.1000388
“Several studies have shown that the selfrenewal capacity of these TICs, which has been attributive of BMI1 overexpression, is involved in prostate cancer initiation and progression prostate cancer [29].”
BackgroundInfluentialThe Effects of the Organ Microenvironment on Metastatic Cell Gene Signatures
Kim, S., Lee, H. J., Yu, H.-K., Choi, S. I., Weinstein, J. N., Wang, J., Qi, Y., & Fidler, I. J. (2017) · Molecular and translational medicine · doi:10.1007/978-3-319-57424-0_5
Glinsky, G. V. (2017) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2017.43
“001) were used for selection of gene sets with common patterns of association and concordance analysis was performed using expression profiling data of snpRNA-driven cell line-based models of prostate cancer predisposition[15,16] to identify concordant and discordant GES in cell lines and clinical samples.[17-20] GES…”
BackgroundMethodInfluentialSelf-citationChanges in the Epigenetic Landscape of Prostate Cancer
Salumbides, B. C., & Meyering, S. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809552-2.00003-6
Felley‐Bosco, E., Opitz, I., Soltermann, A., Thies, S., Weder, W., & Stahel, R. A. (2011) · Zurich Open Repository and Archive (University of Zurich)
Regulation of anoikis by ankyrin complexes
Kumar, S. (2010) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.4620
“Ankyrin-G was one of the 3 down-regulated genes, suggesting its inverse correlation with cancer progression (Glinsky et al., 2005).”
BackgroundThe Cellular Function of USP22 and its Role in Tissue Maintenance and Tumor Formation
Kosinsky, R. L. (2018) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-6724
Tumor-suppressive proteases revisited: Role in inhibiting tumor progression and metastasis
Shukla, D., Mandal, T., Saha, P., Kumar, D., Kumar, S., & Srivastava, A. K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818168-3.00014-0 · Cited by 2
Rehman, S., Haynes, J., Lima‐Fernandes, E., Puri, A., Haller, A., Leung, C., Agro, L. A., Wang, Y., & O'Brien, C. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803892-5.00007-3 · Cited by 2
Hong-qun, W., Li, Y., Ding, S., Li, Y., Wang, A.-C., & Shi, H. (2020) · Translational Cancer Research · doi:10.21037/tcr-20-2102
“Transl Cancer Res 2020;9(5):3703-3711 | http://dx.”
Investigational Molecular Prognostic Factors for Breast Carcinoma
Shah, H., & Nabell, L. M. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-5221-0.00025-5
Stem Cells, the Breast, and Breast Cancer
Wicha, M. S., & Barsky, S. H. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-5221-0.00029-2
Hec1/Ndc80 is overexpressed in human gastric cancer and regulates cell growth
Ract, R. T., & Liu, C. (2014)
Aryaev, N. L., Маричереда, В. Г., Шевченко, И. М., Moskalenko, T. Y., Mezevgi, J. M. E., & Шевченко, Н. В. (2016) · INFM-OAR (INFN Catania) · doi:10.5281/zenodo.153862
Gyan, E., Owiredu, W. K. B. A., Fondjo, L. A., Jackson, A. M., Green, A. R., Toss, M. S., Akakpo, P. K., Derkyi‐Kwarteng, L., & Rahman, G. A. (2021) · Gene Reports · doi:10.1016/j.genrep.2021.101475
Pollack, J. R. (2016) · Springer eBooks · doi:10.1007/978-1-59745-458-2_3
Allen, T. C., & Cagle, P. T. (2008) · Molecular pathology library · doi:10.1007/978-0-387-72430-0_20
Felley‐Bosco, E., & Opitz, I. (2012) · Informa Healthcare eBooks · doi:10.3109/9781841848679.013
Coles, M. C., & Brown, L. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.13360978.793557096
Rosell, R. (2012) · doi:10.2217/ebo.12.4
Liu, X., Doherty, L. M., Felix, A., & Buhrlage, S. J. (2022) · Wiley eBooks · doi:10.1002/9781119774198.ch7
Knockdown of BMI1 is sensitive to Paclitaxel in cervical and endometrial cancerPreprint
Zhao, Y., Lin, Y., Yang, W., Chen, J., & Jin, X. (2023) · Research Square · doi:10.21203/rs.3.rs-2599518/v1
Stammzellentherapie — Frischzellentherapie der Zukunft?
Krämer, A., & Ho, A. D. (2007) · Springer eBooks · doi:10.1007/978-3-540-48562-9_11
Datta, S., Hoenerhoff, M. J., Bommi, P. V., Sainger, R., Guo, W., Dimri, M., Band, H., Band, V., Green, J. E., & Dimri, G. P. (2023) · doi:10.1158/0008-5472.c.6495710
Datta, S., Hoenerhoff, M. J., Bommi, P. V., Sainger, R., Guo, W., Dimri, M., Band, H., Band, V., Green, J. E., & Dimri, G. P. (2023) · doi:10.1158/0008-5472.c.6495710.v1
Schade, B., Lam, S. H. L., Cernea, D. D., Sanguin‐Gendreau, V., Cardiff, R. D., Jung, B. L., Hallett, M. T., & Muller, W. J. (2023) · doi:10.1158/0008-5472.22367729
Guo, W.-J., Zeng, M., Yadav, A. K., Song, L., Guo, B., Band, V., & Dimri, G. P. (2023) · doi:10.1158/0008-5472.c.6495959
Guo, W., Zeng, M., Yadav, A. K., Song, L., Guo, B., Band, V., & Dimri, G. P. (2023) · doi:10.1158/0008-5472.c.6495959.v1
Data from MiR-15a and MiR-16 Control Bmi-1 Expression in Ovarian Cancer
Bhattacharya, R., Nicoloso, M. S., Arvizo, R. R., Wang, E., Cortez, A., Rossi, S., Calin, G. A., & Mukherjee, P. (2023) · doi:10.1158/0008-5472.c.6499994.v1
Wei, J., Yin, L., Li, J., Wang, J., Pu, T., Duan, P., Lin, T.-P., Gao, A. C., & Wu, B. J. (2023) · doi:10.1158/0008-5472.22428616
Lauss, M., Ringnér, M., & Höglund, M. (2023) · doi:10.1158/1078-0432.c.6518544
de Haas, T. G., Hasselt, N. E., Troost, D., Caron, H. N., Popović, M., Zaletel, L. Z., Grajkowska, W., Perek‐Polnik, M., Osterheld, M., Ellison, D. W., et al. (2023) · doi:10.1158/1078-0432.c.6516895.v1
Data from CD44 Expression Predicts Local Recurrence after Radiotherapy in Larynx Cancer
de Jong, M. C., Pramana, J., van der Wal, J. E., Lacko, M., Peutz‐Kootstra, C. J., de Jong, J. M., Takes, R. P., Kaanders, J. H. A. M., van der Laan, B. F. A. M., Wachters, J. E., et al. (2023) · doi:10.1158/1078-0432.c.6518958.v1
Xie, Y., Xiao, G., Coombes, K. R., Behrens, C., Solis, L. M., Raso, G., Girard, L., Erickson, H. S., Roth, J. A., Heymach, J. V., et al. (2023) · doi:10.1158/1078-0432.c.6520209.v1
de Jong, M. C., Pramana, J., van der Wal, J. E., Lacko, M., Peutz‐Kootstra, C. J., de Jong, J. M., Takes, R. P., Kaanders, J. H. A. M., van der Laan, B. F. A. M., Wachters, J. E., et al. (2023) · doi:10.1158/1078-0432.22442151
Wei, J., Yin, L., Li, J., Wang, J., Pu, T., Duan, P., Lin, T.-P., Gao, A. C., & Wu, B. J. (2023) · doi:10.1158/0008-5472.22428616.v1
Jackson‐Spence, F., Ackerman, C., Jones, R. J., Toms, C., Jovaisaite, A., Young, M. R., Hussain, S. A., Protheroe, A. S., Birtle, A. J., Chakraborti, P. R., et al. (2024) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2024.05.015
Habiburrahman, M., Masrour, N., Patel, N. R., Piskorz, A., Brown, R. E., Brenton, J. D., McNeish, I. A., & Flanagan, J. M. (2024) · medRxiv · doi:10.1101/2024.09.18.24312711
Alawam, A. S., & Alamri, M. A. (2025) · Crystals · doi:10.3390/cryst15060507 · Cited by 1
A breast cancer stem cell model created from MMTV-PyMT mice applicable to human breast cancer
Lanza, D. G. (2011) · Scholars Archive - University at Albany (University at Albany, State University of New York) · doi:10.54014/mm9z-ht8x
Damilot, M., Schoeps, T., Tora, L., Schultz, P., Lebeau, L., Pápai, G., & Shem, A. B. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.31.667873
“SAGA is such a large complex that modulates chromatin structure via two enzymatic activities: histone acetylation (HAT) and deubiquitination (DUB)[1].”
Habiburrahman, M., Masrour, N., Patel, N. R., Piskorz, A., Brown, R. E., Brenton, J. D., McNeish, I. A., & Flanagan, J. M. (2025) · International Journal of Cancer · doi:10.1002/ijc.70217 · Cited by 3
“34 We found that shorter PFS strongly predicts mortality and contributes to PLAT-M8 Class 1 status, aligning with research showing that PFS reflects genomic and epigenomic tumour changes, driving poorer survival.”
Metadata
- Authors
- Glinsky, G. V., Berezovska, O., & Glinskii, A. B.
- Affiliations
- Sidney Kimmel Cancer Center (US)
- Corresponding author
- Glinsky, Gennadi V.
- ORCID
- Glinsky, Gennadi V.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-06-01
- Volume
- 115
- Issue
- 6
- Pages
- 1503-1521
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1136989
- OpenAlex
- W2166666333
- Cited by
- 916
- References
- 68
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 22 · 2023: 30 · 2022: 25 · 2021: 29 · 2020: 25 · 2019: 27 · 2018: 38 · 2017: 35 · 2016: 30 · 2015: 50 · 2014: 57 · 2013: 51 · 2012: 60
- FWCI
- 34.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Memorial Sloan-Kettering Cancer Center
- National Institutes of Health
- National Cancer Institute (5R01CA89827, R01CA089827)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Keywords
- cancer stem cells, BMI1, stem cell self-renewal, gene expression signatures, metastasis, treatment failure, prognosis, distant metastasis, recurrence, epithelial malignancies, hematologic malignancies, multi-cancer analysis
- MeSH terms
- Animals, Female, Humans, Male, Mice, Transgenic, Neoplasm Metastasis, Neoplasm Recurrence, Local, Neoplasms, Nuclear Proteins, Prognosis, Proto-Oncogene Proteins, Repressor Proteins, Biomarkers, Tumor, Neoplastic Stem Cells, Gene Expression Regulation, Neoplastic, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Mice, Polycomb Repressive Complex 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.